VRTX · News · 20260810N
Licensing / Collaboration Deals
VERTEX PHARMACEUTICALS INC / MA · 2026-08-10 · Importance 34 · Surprise 42 · In source text
Vertex entered a collaboration with AbCellera for multispecific T-cell engagers. The agreement provides AbCellera with $28 million in upfront consideration. The collaboration is intended to diversify Vertex’s pipeline into additional therapeutic modalities beyond its core cystic fibrosis business.
Key facts
- Vertex Pharmaceuticals announced a new collaboration with AbCellera for multispecific T-cell engagers. source
- The AbCellera–Vertex collaboration included $28 million upfront to AbCellera as part of the deal. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | committed | -0.7% | The AbCellera–Vertex collaboration included $28 million upfront to AbCellera as part of the deal. |
| cash | negative | committed | -0.1% | The AbCellera–Vertex collaboration included $28 million upfront to AbCellera as part of the deal. |